Trials / Completed
CompletedNCT00673842
Efficacy of Implantable Defibrillator Therapy After a Myocardial Infarction
Risk Estimation Following Infarction Noninvasive Evaluation - ICD Efficacy
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 700 (estimated)
- Sponsor
- University of Calgary · Academic / Other
- Sex
- All
- Age
- 18 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
This study will assess whether an implantable defibrillator will increase the likelihood of survival in patients who have had a heart attack, have abnormal test results from a 24 hour heart monitor, and who have low normal heart function.
Detailed description
The REFINE ICD trial will assess whether prophylactic ICD therapy, guided by non-invasive risk assessment tools, reduces mortality in MI survivors with better-preserved LV function.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DEVICE | Implantable Cardioverter Defibrillator + Usual Care | Any Medtronic approved single chamber or dual chamber implantable cardioverter defibrillator (ICD) |
| OTHER | Usual care | Usual post-MI care |
Timeline
- Start date
- 2011-04-18
- Primary completion
- 2024-10-31
- Completion
- 2024-10-31
- First posted
- 2008-05-07
- Last updated
- 2025-05-30
Locations
79 sites across 15 countries: United States, Belgium, Canada, Finland, France, Germany, Hungary, Italy, Norway, Saudi Arabia, Slovakia, South Africa, Spain, Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT00673842. Inclusion in this directory is not an endorsement.